PARP1 and neoplasm: Given the paucity of tractable in vivo models of SSTR2-expressing NET has limited the development of novel therapeutic approaches in this setting, the aims of the study were therefore to characterise a panel of cell lines with neuroendocrine features to identify models appropriate for evaluating the anti-tumour activity of combination regimens incorporating SSTR2-targeted PRRT and then employ the model in vivo to evaluate the efficacy of the PARP inhibitor, talazoparib in combination with LuTate PRRT.